Apoquel (oclacitinib maleate) is the Janus kinase (JAK) inhibitor that reframed canine allergic dermatitis. Approved by the FDA on May 14, 2013 (NADA 141-345) as the first JAK inhibitor for veterinary use, it is indicated for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. For a dog that has been cycling through steroids and cyclosporine, a twice-daily-then-once-daily tablet that starts working in days filled a gap nothing else did — and allergic dermatitis is the single most common insured condition in dogs, so the prescription volume is enormous.

To put real numbers on what that scale of use has produced, VetMedGuide analyzed the FDA Center for Veterinary Medicine (CVM) public adverse-event database, a public extract dated June 2026 containing 1.34 million reports. We identified 29,296 reports naming oclacitinib and tabulated their reactions, outcomes, and reporting history.

The headline is the opposite of what most owners expect. The single most-reported reaction is not a side effect at all — it is lack of efficacy: the drug stopped controlling the itch. Gastrointestinal upset matches the label, the laboratory abnormalities the label tells veterinarians to monitor for show up exactly where predicted, and a modest block of deaths and neoplasia reports appears in a population where both are common regardless of medication. The serious rate is far lower than newer injected drugs generate, and the most useful thing the dataset does is separate what owners actually report from what the internet worries about.

How we identified reports

The FDA's public database masks brand names — every product is recorded as "MSK" — so a drug must be identified by its active ingredient. Oclacitinib is unique to Apoquel (and its 2023 chewable formulation), so we matched reports whose active-ingredient field named it. We worked from the event-level file (one record per unique adverse-event report) rather than the per-reaction rollup, so each report is counted once even when it lists many reactions. The FDA explicitly cautions that spontaneous reports do not establish causation or true event rates.

The most-reported reaction is that the drug stopped working

Add the three efficacy terms together and roughly 8,100 of 29,296 reports — more than a quarter — are complaints that the drug did not control the disease, not reports of harm. This is the dominant signal in the dataset and it is underdiscussed. Oclacitinib controls pruritus in roughly two-thirds of atopic dogs well enough that owners notice, which means a substantial minority have an incomplete response, lose response over time, or flare despite the medication. Those dogs drive the largest block of reports, and they are also the dogs most likely to be layered onto additional therapies (topicals, immunotherapy, cytopoint, antimicrobials for secondary infection) — which is the correct clinical move rather than simply escalating the dose.

The safety cluster that follows reads exactly like the label. Vomiting and diarrhea are the adverse effects the package insert names first. Behind them sit the laboratory abnormalities the label tells veterinarians to monitor for: elevated ALT (1,134) and elevated alkaline phosphatase (1,056) pointing at hepatic enzyme induction, and leukopenia (878) reflecting the JAK-mediated effect on white blood cell production. Periodic bloodwork on long-term oclacitinib is recommended precisely because these changes are predictable and usually manageable when caught early — the spontaneous data confirms why that monitoring exists.

The neoplasia question the data can hint at but not resolve

No discussion of oclacitinib avoids the cancer question for long, so it is worth stating plainly what the database does and does not show. The label warns that oclacitinib "may exacerbate neoplastic conditions," dogs with pre-existing neoplasia were excluded from the registration studies, and the FDA's 2018 untitled letter to Zoetis pushed back on promotional language implying the drug was "safe" with only minimal side effects. Within these reports, a fatal outcome appears in 1,435 cases (791 euthanized, 644 died), and "death by euthanasia" sits among the top reported reactions.

But that number cannot be read as a cancer signal, for three reasons the dataset itself makes obvious. First, atopic dermatitis is a disease of adult and senior dogs, and cancer — particularly mast cell tumors, which are overrepresented in the breeds most prone to atopy (Labrador and Golden Retrievers, Staffordshire Terriers, Boston Terriers) — is common in that same aging population regardless of medication. Second, the controlled studies did not find an excess of cancer on oclacitinib: an age- and breed-matched retrospective cohort of 660 dogs found malignancy in 16.5% of oclacitinib-treated dogs versus 12.8% of controls on other allergy therapies — a difference that was not statistically significant — and the age at death was equivalent between groups. Third, spontaneous reports count whatever was happening when the drug was given; they cannot establish that oclacitinib caused, accelerated, or even coincided meaningfully with a tumor.

What the data does corroborate is the label's monitoring instruction: a dog on long-term oclacitinib should be watched for the development of infections (urinary tract, respiratory, skin, including demodicosis) and for new masses on or under the skin. Those are surveillance steps, not reasons to avoid a drug that works well for many dogs — but they are the steps the reporting volume justifies.

A lower serious rate than injected drugs, and a reporting curve with two humps

Two things stand out. The serious rate — 8,592 of 29,296 reports, or 29.3% — is markedly lower than the injected monoclonal antibodies analyzed in the same database (Librela's bedinvetmab runs above 60%), which partly reflects that oclacitinib's most common reports are efficacy complaints and manageable GI signs rather than the acute neurologic and death events that drive "serious" flags. And the reporting curve has two humps: a peak around 2016–2017 as the drug reached saturation after launch, a decline through the pandemic years, and a clear rebound in 2024–2025 — consistent with the 2023 launch of the chewable formulation and the post-pandemic surge in dermatology visits. Reporting volume tracks usage, not just risk.

One additional signal worth naming: overdose or accidental ingestion appears in 873 reports. This is why the 2020 label update added a note recommending oclacitinib be stored securely — chewable or palatable formulations get into dogs that should not have them, and the spontaneous data is the reason that line is in the insert.

What to take into the exam room

• Set the efficacy expectation honestly. Roughly a third of atopic dogs will need more than oclacitinib alone. Plan for adjunct therapy and follow-up rather than assuming one tablet resolves a chronic disease.
• Do the bloodwork the label asks for. Elevated liver enzymes and leukopenia are predictable, detectable early, and usually manageable. A baseline and periodic recheck are the point, not a formality.
• Watch for infections and new masses. Both are label monitoring items, and both appear in the data. A new lump or a recurrent infection on long-term oclacitinib is a reason to examine, not a reason to panic.
• Store it where the dog cannot reach it. The overdose reports are real, and they are preventable.

Sources

• FDA CVM, animal adverse-event database (public extract, June 2026); analysis by VetMedGuide. The FDA cautions that spontaneous reports do not establish causation or true event rates. https://www.fda.gov/animal-veterinary/safety-health/reporting-animal-drug-and-device-side-effects-and-product-problems
• FDA, Freedom of Information Summary, NADA 141-345, Apoquel (oclacitinib tablet), original approval May 14, 2013 (dogs ≥12 months; pruritus associated with allergic dermatitis and atopic dermatitis). https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/902
• FDA, Untitled Letter to Zoetis regarding Apoquel promotional claims (NADA 141-345) — risk minimization, "safe" language, neoplasia and infection monitoring. https://www.fda.gov/media/113909/download
• Apoquel (oclacitinib maleate tablet) prescribing information / package insert, Zoetis (warnings, precautions, post-approval experience). https://www.zoetisus.com/content/_assets/docs/vmips/package-inserts/apoquel-prescribing-information.pdf
• Zoetis, "FDA Approves APOQUEL (oclacitinib tablet)" — approval announcement and clinical study results (May 14, 2013). https://news.zoetis.com/press-releases/press-release-details/2013/FDA-Approves-APOQUEL-oclacitinib-tablet-to-Control-Itch-and-Inflammation-in-Allergic-Dogs/default.aspx
• Snyder S, et al. "Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs" (label evolution, 2013 vs 2020 neoplasia language, post-approval experience section). https://pmc.ncbi.nlm.nih.gov/articles/PMC12066884
• Olivry T, et al. "Oclacitinib 10 years later: lessons learned and directions for the future." JAVMA, 2023;261(S1). https://avmajournals.avma.org/view/journals/javma/261/S1/javma.22.12.0570.xml
• Lancellotti BA, Angus JC, Edginton HD, Rosenkrantz WS. "Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib." JAVMA, 2020;257(5):507–516. https://avmajournals.avma.org/view/journals/javma/257/5/javma.257.5.507.xml